MDM2 splice variants predominantly localize to the nucleoplasm mediated by a COOH-terminal nuclear localization signal

Molecular Cancer Research

Volumn 5, Issue 4, 2007, Pages 403-412

  Schuster, Katja ^a   Fan, Liying ^a   Harris, Linda C ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN VARIANT; SITE DIRECTED MUTAGENESIS;

ANIMALS; BINDING SITES; CELL NUCLEUS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; MICE; MOLECULAR SEQUENCE DATA; NUCLEAR LOCALIZATION SIGNALS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34248185149     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0146     Document Type: Article

References (24)

1. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences; transforming ability and frequent detection in human cancer. Nat Med 1996;2:912-7.
2. Matsumoto R, Tada M, Nozaki M, Zhang CL, Sawamura Y, Abe H. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res 1998;58:609-13.
3. Bartel F, Meye A, Wurl P, et al. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 mRNA is associated with prognosis in soft tissue sarcoma. Int J Cancer 2001;95:168-75.
4. Tamborini E, Della Torre G, Lavarino C, et al. Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas. Int J Cancer 2001;92:790-6.
5. Bartel F, Taylor AC, Taubert H, Harris LC. Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. Oncol Res 2002;12:451-7.
6. Lukas J, Gao DQ, Keshmeshian M, et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 2001;61:3212-9.
7. Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002;2:9-15.
8. Brown DR, Thomas CA, Deb SP. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 1998;17:2513-25.
9. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 2001;20:4041-9.
10. Evdokiou A, Atkins GJ, Bouralexis S, et al. Expression of alternatively-spliced MDM2 transcripts in giant cell tumours of bone. Int J Oncol 2001;19:625-32.
11. Lohrum MA, Ashcroft M, Kubbutat MH, Vousden KH. Identification of a cryptic nucleolar-localization signal in MDM2. Nat Cell Biol 2000;2:179-81.
12. Dang J, Kuo ML, Eischen CM, Stepanova L, Sherr CJ, Roussel MF. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res 2002;62:1222-30.
13. Roberts B. Nuclear location signal-mediated protein transport. Biochim Biophys Acta 1989;1008:263-80.
14. Weber JD, Kuo ML, Bothner B, et al. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol 2000;20:2517-28.
15. Kinkema M, Fan W, Dong X. Nuclear localization of NPR1 is required for activation of PR gene expression. Plant Cell 2000;12:2339-50.
16. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 2001;98:11598-603.
17. Rubbi CP, Milner J. Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus. Oncogene 2000;19:85-96.
18. Lindstrom MS, Klangby U, Inoue R, Pisa P, Wiman KG, Asker CE. Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus. Exp Cell Res 2000;256:400-10.
19. Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 protein in the cell cycle requires nuclear localization. Cell Growth Differ 1991;2:661-7.
20. Shaulsky G, Goldfinger N, Tosky MS, Levine AJ, Rotter V. Nuclear localization is essential for the activity of p53 protein. Oncogene 1991;6:2055-65.
21. Tao W, Levine AJ. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A 1999;96:6937-41.
22. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999;1:20-6.
23. Persons DA, Allay JA, Allay ER, et al. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 1997;90:1777-86.
24. Pirollo KF, Hao Z, Rait A, et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997;14:1735-46.